From an interview conducted during Patient-Centered Oncology Care 2023.
Lucy Langer, MD, MSHS, national medical director of oncology and genomics at UnitedHealthcare, shares with Evidence-Based Oncology her perspective on the current state of oncology clinical pathways and how they can lead to confusion and burnout among providers.
The topic was discussed further among the panel discussion “Can Clinical Pathways Have Burnout, Too?” at Patient-Centered Oncology Care 2023.
EBO: Can you share your perspective on the current state of oncology clinical pathways?
Langer: As we all know, there’s a multitude of clinical pathways that are available now. Many organizations have gotten into the pathways-building business, starting with providers, but payers and private companies as well. And while all pathways are built on the same principles—meaning outcomes first followed by toxicity, and then when there are equivalent regimens, using real-world evidence or using cost or some other arbiter to determine what would be on pathways and what would not—even though we’re all using basically the same principles, somehow we’ve come to slightly different variations of pathways.
I’d say right now there’s a lot of noise in the system. And as a specialty, I think there’s an opportunity for us to come together and collaborate on what we consider to be high-quality care delivery in oncology and strive toward our common shared goals, which are to ensure that patients with cancer get the highest-quality care that they can, but we also keep it affordable, accessible, and sustainable.
EBO: Based on your panel, how can clinical pathways lead to added stress and burnout?
Langer: We started out talking about the multiplicity of pathways that are available, and I think it’s complicated and it’s confusing for providers, and I think providers sometimes mistake pathways for what we will or will not cover. At least at UnitedHealthcare, our pathways program is only additive; it’s not a punitive program. Our coverage policies are very broad, so providers get rewarded for knowing our pathways and for prescribing on our pathways, but they’re not penalized for not doing so.
I think it’s also important to know that the pathways programs that are out there are all striving for high-quality care. I think what we need to do to go forward to kind of find our way out of the confusion or maybe the burnout that providers are feeling is to really come to the table and collaborate about what we think is the indicator for high-quality care and agree on that. If that’s a certain pathways program, if it’s the NCCN [National Comprehensive Cancer Network], if it’s some other indicator, if we all agree as a specialty, then we can use that to move forward to reward high-quality, high-value care.
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Breast Cancer Treatment Disparities Impact Survival Based on Race, Age, Socioeconomics
May 9th 2024A new study has linked racial and ethnic disparities with factors like age, income, and insurance to breast cancer treatment decline. Patients who received all treatments had better survival, highlighting the need for interventions to improve access and reduce disparities.
Read More